Destiny Pharma
Destiny Pharma is a clinical phase biotechnology company dedicated to the development of novel anti-infectives with a focus on infection prevention. They aim to address post-surgical infections, antimicrobial resistance, and Clostridioides difficile infections through innovative medicines and biotherapeutic products. The company actively seeks partnerships for the development and commercialization of its portfolio.
Industries
Nr. of Employees
small (1-50)
Destiny Pharma
Brighton, East Sussex, United Kingdom, Europe
Products
Nasal prophylactic for prevention of post-surgical staphylococcal infection
A nasal prophylactic formulation from an antimicrobial platform developed to reduce post-surgical staphylococcal infections; has completed clinical studies and holds expedited regulatory designations in the US.
Dermal formulation for treatment of bacterial skin infections
A topical dermal formulation developed to treat skin infections, including those caused by antibiotic-resistant bacteria and in contexts such as burn wounds or open skin lesions; has received government-supported development funding.
Anti-biofilm drug research programmes
Research projects focused on developing agents active against antibiotic-resistant biofilms and bacterial aggregates for respiratory, dermal and oral mucosal applications.
Single-strain live biotherapeutic for prevention of recurrent CDI
A single-strain non-toxigenic live biotherapeutic product developed to prevent recurrence of Clostridioides difficile infection; company holds global rights and has engaged licensing partners for regional development.
Nasal prophylactic for prevention of post-surgical staphylococcal infection
A nasal prophylactic formulation from an antimicrobial platform developed to reduce post-surgical staphylococcal infections; has completed clinical studies and holds expedited regulatory designations in the US.
Dermal formulation for treatment of bacterial skin infections
A topical dermal formulation developed to treat skin infections, including those caused by antibiotic-resistant bacteria and in contexts such as burn wounds or open skin lesions; has received government-supported development funding.
Anti-biofilm drug research programmes
Research projects focused on developing agents active against antibiotic-resistant biofilms and bacterial aggregates for respiratory, dermal and oral mucosal applications.
Single-strain live biotherapeutic for prevention of recurrent CDI
A single-strain non-toxigenic live biotherapeutic product developed to prevent recurrence of Clostridioides difficile infection; company holds global rights and has engaged licensing partners for regional development.
Services
Partnering and licensing for development-stage anti-infectives
Structuring and negotiating collaboration, licensing, investment and joint-venture arrangements to advance development and commercialisation of anti-infective assets.
Partnering and licensing for development-stage anti-infectives
Structuring and negotiating collaboration, licensing, investment and joint-venture arrangements to advance development and commercialisation of anti-infective assets.
Expertise Areas
- Infection prevention therapeutics
- Clinical trial management for anti-infectives
- Anti-infective and anti-biofilm R&D
- Live biotherapeutic development for CDI
Key Technologies
- Antimicrobial small-molecule platform with rapid bactericidal mechanism
- Live biotherapeutic products (single-strain LBP)
- Anti-biofilm therapeutic approaches
- Nasal and dermal topical formulation platforms